http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Salva+Francisco+D./26666597.html si-local-file:///var/storage/secattach/20260618/26666597.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Salva+Francisco+D./26666597.html Thu, 18 Jun 2026 16:31:00 -0400 AZTR O.30875120 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Salva+Francisco+D./26666597.html si-local-file:///var/storage/secattach/20260618/26666597.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Salva+Francisco+D./26666597.html Thu, 18 Jun 2026 16:31:00 -0400 AZTR O.30875120 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+17/26657189.html si-local-file:///var/storage/secattach/20260617/26657189.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+17/26657189.html Wed, 17 Jun 2026 08:06:00 -0400 AZTR O.30875120 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+17/26657189.html si-local-file:///var/storage/secattach/20260617/26657189.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+17/26657189.html Wed, 17 Jun 2026 08:06:00 -0400 AZTR O.30875120 http://www.streetinsider.com/Corporate+News/Azitra+expands+into+cosmetics+and+biotech+after+%2410.5M+financing/26657160.html <p>Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, outlined a strategic expansion into cosmetic ingredients and biotechnology products in a shareholder letter issued by Chief Executive Officer Francisco Salva.</p><p>The company said a March 2026 financing that raised $10.5 million, with up to an additional $21 million available through warrant exercises, is funding the new initiatives.</p><p>One new program, ATR-COSF, is a recombinant filaggrin protein candidate targeting the cosmetic skincare market, specifically aimed at reducing the appearance of fine lines and wrinkles. The company said it is conducting product optimization and ex vivo human skin studies and http://www.streetinsider.com/Corporate+News/Azitra+expands+into+cosmetics+and+biotech+after+%2410.5M+financing/26657160.html Wed, 17 Jun 2026 08:03:23 -0400 AZTR http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span> ("<span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that <person>Francisco Salva</person>, Chief Executive Officer of <span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra</span>, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+CEO+Issues+Letter+to+Shareholders+Detailing+Strategic+Reorientation+Initiatives+and+Outlook+for+2026+and+Beyond/26657031.html Wed, 17 Jun 2026 08:00:00 -0400 A.33615634 AZTR O.07116439 O.30875120 http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ct.braord" idsrc="xmltag.org" >BRANFORD, Conn.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713341-1&amp;h=1894926616&amp;u=https%3A%2F%2Fazitrainc.com%2F&amp;a=Azitra%2C+Inc." target="_blank" rel="nofollow"><span value="AMEX:AZTR" idsrc="xmltag.org" >Azitra, Inc.</span></a> (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, <person>Travis Whitfill</person> Ph.D., MPH, will present at <span>BIO International Convention</span>, being held <chron>June 22-25, 2026</chron>, in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Azitra%2C+Inc.+to+Present+at+2026+BIO+International+Convention/26655362.html Tue, 16 Jun 2026 17:28:00 -0400 A.33934625 AZTR O.21005812 O.30875120 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+15/26650781.html si-local-file:///var/storage/secattach/20260616/26650781.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+15/26650781.html Tue, 16 Jun 2026 08:02:00 -0400 AZTR O.30875120 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+15/26650781.html si-local-file:///var/storage/secattach/20260616/26650781.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Azitra%2C+Inc.++++++++++++++For%3A+Jun+15/26650781.html Tue, 16 Jun 2026 08:02:00 -0400 AZTR O.30875120 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Azitra%2C+Inc.+++++++++++++++++++++++++/26605912.html si-local-file:///var/storage/secattach/20260604/26605912.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Azitra%2C+Inc.+++++++++++++++++++++++++/26605912.html Thu, 04 Jun 2026 16:16:00 -0400 AZTR O.30875120 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Azitra%2C+Inc.+++++++++++++++++++++++++/26605912.html si-local-file:///var/storage/secattach/20260604/26605912.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Azitra%2C+Inc.+++++++++++++++++++++++++/26605912.html Thu, 04 Jun 2026 16:16:00 -0400 AZTR O.30875120